First case series on the use of imiquimod for morphoea

被引：71

作者：

Dytoc, M ^{[1
]}

Ting, PT

Man, J

Sawyer, D

Fiorillo, L

机构：

[1] Univ Alberta, Div Dermatol & Cutaneous Sci, Edmonton, AB T6G 2G3, Canada

[2] Univ Calgary, Fac Med, Calgary, AB, Canada

[3] Univ Alberta, Fac Med, Edmonton, AB, Canada

[4] Red Deer Reg Hosp, Dept Pathol, Red Deer, AB, Canada

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2005年 / 153卷 / 04期

关键词：

cytokines; imiquimod; localized scleroderma; morphoea;

D O I：

10.1111/j.1365-2133.2005.06776.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 [皮肤病与性病学];

摘要：

Background Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta. Objective Our objective was to use imiquimod 5% cream (Aldara (TM)), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea. Methods Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months. Results The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness. Conlcusion This is the first case series describing the successful application of imiquimod in the management of morphoea.

引用

页码：815 / 820

页数：6

共 19 条

[1]

BERMAN B, 1993, DERMAL IMMUNE SYSTEM, P209

[2]

BORDER WA, 1994, NEW ENGL J MED, V331, P1286

[3]

GILLERY P, 1992, EUR J CELL BIOL, V57, P244

[4]

SIGNIFICANT CORRELATION BETWEEN CONNECTIVE-TISSUE GROWTH-FACTOR GENE-EXPRESSION AND SKIN SCLEROSIS IN TISSUE-SECTIONS FROM PATIENTS WITH SYSTEMIC-SCLEROSIS [J].